1. Home
  2. SUPN vs TSLX Comparison

SUPN vs TSLX Comparison

Compare SUPN & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • TSLX
  • Stock Information
  • Founded
  • SUPN 2005
  • TSLX 2010
  • Country
  • SUPN United States
  • TSLX United States
  • Employees
  • SUPN N/A
  • TSLX N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • TSLX Investment Managers
  • Sector
  • SUPN Health Care
  • TSLX Finance
  • Exchange
  • SUPN Nasdaq
  • TSLX Nasdaq
  • Market Cap
  • SUPN 2.6B
  • TSLX 2.2B
  • IPO Year
  • SUPN 2012
  • TSLX 2014
  • Fundamental
  • Price
  • SUPN $45.66
  • TSLX $23.40
  • Analyst Decision
  • SUPN Buy
  • TSLX Buy
  • Analyst Count
  • SUPN 2
  • TSLX 9
  • Target Price
  • SUPN $43.00
  • TSLX $23.39
  • AVG Volume (30 Days)
  • SUPN 654.2K
  • TSLX 354.1K
  • Earning Date
  • SUPN 11-03-2025
  • TSLX 11-04-2025
  • Dividend Yield
  • SUPN N/A
  • TSLX 8.83%
  • EPS Growth
  • SUPN 1411.53
  • TSLX N/A
  • EPS
  • SUPN 1.14
  • TSLX 2.01
  • Revenue
  • SUPN $665,125,000.00
  • TSLX $474,291,000.00
  • Revenue This Year
  • SUPN $4.84
  • TSLX N/A
  • Revenue Next Year
  • SUPN $17.69
  • TSLX N/A
  • P/E Ratio
  • SUPN $38.93
  • TSLX $11.68
  • Revenue Growth
  • SUPN 5.55
  • TSLX 0.15
  • 52 Week Low
  • SUPN $29.16
  • TSLX $18.58
  • 52 Week High
  • SUPN $46.79
  • TSLX $25.17
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 62.59
  • TSLX 36.68
  • Support Level
  • SUPN $43.44
  • TSLX $23.14
  • Resistance Level
  • SUPN $46.72
  • TSLX $23.59
  • Average True Range (ATR)
  • SUPN 1.12
  • TSLX 0.34
  • MACD
  • SUPN -0.41
  • TSLX -0.15
  • Stochastic Oscillator
  • SUPN 68.96
  • TSLX 15.81

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: